Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.
Also called NCT04899479
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT04899479
-
- Other papers using this trial's data
- SGLT2 Inhibitor on Infarct Size and LV Remodeling by CMR in Patients With AMI
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT04899479. Randomized; no masking; primary purpose treatment. Start 2021-07-05 (actual); primary completion 2025-08-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention
- Acronym
- PRESTIGE-AMI
- Condition
- Acute Myocardial Infarction
- Condition
- Heart Failure
- Intervention (Drug)
- SGLT2 inhibitor
- Intervention (Other)
- Control
- Lead sponsor
- Samsung Medical Center
Record details
- Record id
cardio:ct-nct04899479- Content hash
c9ca293fd41c889138941c38ab09f5a2c4bdb038c897a8da06e733151ace675f